7 things to know about Foundayo, a next-generation weight-loss pill

There’s always a media buzz when a new weight-loss drug hits the market. Or when new data shows that a medication can effectively lower body weight.

If you've been exploring medication options to help you manage your weight, you may have stumbled across injections, such as Wegovy (semaglutide) and Zepbound (tirzepatide). For some, the thought of regularly giving yourself injections may seem overwhelming or uncomfortable.

New weight-loss pills are hitting the shelves as alternative options to injectable glucagon-like peptide-1 (GLP-1) receptor agonists. Oral Wegovy (semaglutide) tablets started the trend in December 2025, and Foundayo (orforglipron) tablets followed suit in April 2026.

GoodRx, a platform for medication savings, covers seven things to know about Foundayo for weight loss.

Key takeaways:

• Foundayo (orforglipron) is a new prescription weight-loss pill. It’s FDA-approved for adults who are considered obese, or overweight with at least one weight-related health condition, such as high blood pressure or high cholesterol.
• Foundayo is an alternative to injectable glucagon-like peptide-1 (GLP-1) receptor agonists like Zepbound (tirzepatide). It’s part of a growing class of oral GLP-1s, including oral Wegovy (semaglutide), that offer a needle-free approach to weight loss.
• Foundayo is a convenient, once-daily pill. You can take it with or without food, unlike other oral options.
• Phase 3 study results for Foundayo found that the medication helped people lose an average of about 11% of their initial body weight with the highest dose after 72 weeks. Its side effects are similar to those of injectable GLP-1 receptor agonists.

1. Foundayo is FDA-approved for certain adults with a larger body size

Foundayo is FDA-approved to help adults lose excess body weight and maintain weight loss long term. It’s approved for adults who are considered obese, or overweight with at least one weight-related health condition. Examples of qualifying conditions include high blood pressure, high cholesterol levels, and obstructive sleep apnea.

If you receive a prescription for Foundayo, you should take it along with a reduced-calorie diet and routine physical activity. Lifestyle changes like these give Foundayo the foundation to be successful.

Foundayo is made by Eli Lilly, the same company that makes Zepbound (tirzepatide), Trulicity (dulaglutide), and many other diabetes medications.

2. Foundayo is a convenient, once-daily medication

Foundayo is a once-daily oral tablet. It comes in six-tablet doses, ranging from 0.8 mg to 17.2 mg. You can take Foundayo with or without food, and it doesn’t have food or water restrictions. This flexibility is different from medications such as oral Wegovy.

When you first start Foundayo, you’ll slowly increase your dose over time. This is done to help lower the risk of stomach-related side effects. The typical starting dosage is 0.8 mg once daily. After at least 30 days, the dose is increased to 2.5 mg once daily, then to 5.5 mg once daily after at least another 30 days. If needed, the dose can be increased stepwise to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each dose. This will be based on your response and how well you tolerate the dose. The maximum dosage is 17.2 mg once daily.

You should swallow the tablets whole. Don’t break, crush, or chew them. You shouldn’t take Foundayo with another GLP-1 receptor agonist, either.

3. Foundayo is part of a new class of ‘glipron’ medications

“Gliprons” are a new group of GLP-1 medications used for weight loss. Their name comes from the ending of their generic names. They don’t end in “tide” like other GLP-1s because they aren’t peptides.

They do work like other GLP-1s, though. They mimic the effects of the natural GLP-1 hormone that helps regulate blood glucose (blood sugar) and appetite, among other effects.

Foundayo is the first approved medication in this group. There’s another possible glipron on the horizon, called aleniglipron. This medication is still being studied and isn’t approved yet.

Good to know: Try not to confuse gliprons with gliptins. Gliptins are a different group of Type 2 diabetes medications. Januvia (sitagliptin) and Tradjenta (linagliptin) are two common gliptins.

4. Foundayo isn't a peptide like other GLP-1 medications

Foundayo is similar to other GLP-1 receptor agonists, generally speaking. But it's made using different materials and processes.

Traditional GLP-1 receptor agonists, such as Wegovy, are peptides (chains of amino acids) that resemble the GLP-1 hormone. This hormone plays a role in digestion and blood glucose (sugar) regulation. These medications mimic GLP-1’s natural effects, helping you feel fuller for longer and lessening your appetite. This often leads to weight loss.

But these peptides can’t travel through your stomach very well due to their size. Plus, enzymes (proteins) and acids in your gut can break peptides apart, rendering them ineffective. This is why they’re typically made as injections, not pills. Oral options, such as Rybelsus (semaglutide) and oral Wegovy, are made with absorption-enhancing ingredients and have specific instructions for use.

Gliprons, which are not peptides, address this issue. Like many other medications, they’re small-molecule drugs made using chemical synthesis rather than specialized processes like recombinant DNA technology. They’re able to start working after you swallow a dose and don’t generally need to be timed around meals. Dubbed “nonpeptide” GLP-1 receptor agonists, they activate GLP-1 in their own way.

As an added bonus, small-molecule drugs tend to be easier and cheaper to produce in bulk compared to peptides. This may translate to additional savings at the pharmacy.

5. Foundayo is an effective treatment for weight loss

Several clinical trial results are available for Foundayo. Here’s what studies say about its effectiveness so far.

Foundayo weight-loss benefits

Recent results from Foundayo’s phase 3 ATTAIN-1 trial showed that people taking the highest dose for 72 weeks (about 17 months) lost an average of about 11% of their initial body weight.

Foundayo may also be a good option if you want to switch from an injectable GLP-1 medication to a pill. In clinical studies, people who switched from Zepbound or Wegovy were able to keep off the weight they had already lost.

Foundayo Type 2 diabetes benefits

Eli Lilly reported that Foundayo met its main goals in phase 3 trials for Type 2 diabetes. It lowered hemoglobin A1C (HbA1C) levels more than comparison treatments and also supported weight loss.

For instance, in one head-to-head study, the highest dose of Foundayo lowered A1C by 2.2% compared to 1.4% with Rybelsus. People taking the highest dose of Foundayo lost about 20 pounds on average, too. Some people noticed benefits within the first four weeks of starting Foundayo.

In addition to weight loss and lower A1C, several people also saw improvements in cholesterol, triglycerides, and blood pressure.

Eli Lilly plans to seek FDA approval for Foundayo to treat Type 2 diabetes and obesity in 2026.

6. Foundayo’s side effects are similar to those of other GLP-1 receptor agonists

All medications can cause side effects, including Foundayo. Clinical studies suggest that Foundayo has similar side effects to injectable GLP-1 receptor agonists. Nausea, diarrhea, and stomach pain are all possible complaints.

Common or mild Foundayo side effects include:

• Nausea or vomiting
• Constipation
• Diarrhea
• Indigestion
• Stomach pain
• Headache
• Bloating
• Fatigue
• Heartburn
• Gas (flatulence)
• Hair loss or thinning

Rare but serious Foundayo risks include:

• Thyroid C-cell tumors, including a boxed warning about possible thyroid tumors.
• Inflammation of the pancreas (pancreatitis).
• Severe stomach or digestive problems.
• Kidney problems, especially from dehydration.
• Low blood sugar, especially if taken with insulin or certain diabetes medications.
• Worsening eye problems for people with Type 2 diabetes.
• Gallbladder problems (such as gallstones).
• Food or liquid entering the lungs during surgery or procedures that require anesthesia.

Contact your prescriber if you develop any bothersome side effects at any point. But if anything feels severe, listen to your body. Call 911 or go to the nearest ER right away.

7. Certain people shouldn’t take Foundayo

Certain people shouldn’t take Foundayo. It’s not recommended if you have:

• A personal or family history of a rare thyroid cancer called medullary thyroid carcinoma.
• Multiple endocrine neoplasia syndrome type 2, a rare genetic disorder.
• Severe gastroparesis (slow stomach emptying).
• A serious allergy to orforglipron or any of its inactive ingredients.

You should stop taking Foundayo if you become pregnant, as it may harm a developing fetus. It can also make birth control pills less effective. If you take oral contraceptives, talk to your care team. They may advise you to switch to a non-oral method (like an implant) or to use a barrier method (like condoms) for 30 days after starting Foundayo and for 30 days after each dose increase.

Children or teens should not take Foundayo. It’s currently only approved for adults.

The bottom line

Foundayo (orforglipron) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. It’s FDA-approved for adults with obesity or adults who are overweight and have at least one weight-related health condition, such as high blood pressure or high cholesterol.

Unlike traditional GLP-1 receptor agonists, Foundayo is a small molecule drug — not a peptide. It’s an effective treatment option for weight loss, and it may be approved for Type 2 diabetes later on.

This story was produced by GoodRx and reviewed and distributed by Stacker.